On November 25, 2024, Jonathan Hunt, Chief Financial Officer of Perspective Therapeutics Inc, purchased 12,829 shares of the company. Following this transaction, the insider now owns a total of 48,800 shares. The details of this transaction can be found in the SEC Filing.
Perspective Therapeutics Inc (CATX, Financial) is a company engaged in the development and commercialization of innovative therapeutic solutions. The company focuses on advancing its pipeline of products to address unmet medical needs.
The insider's recent purchase is part of a broader trend within the company. Over the past year, there have been 20 insider buys and no insider sells, indicating a pattern of confidence among the company's insiders.
As of the date of the transaction, shares of Perspective Therapeutics Inc were trading at $3.82, giving the stock a market cap of $297.385 million. The company's stock is currently considered Significantly Overvalued based on its GF Value of $0.17, resulting in a price-to-GF-Value ratio of 22.47.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This insider buying activity by Jonathan Hunt, along with the overall trend of insider purchases, may be of interest to investors monitoring the company's stock performance and valuation.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
